Veloxis Pharmaceuticals A/S announced that it is raising its Outlook for 2019. The company revised its 2019 outlook of revenues to be in the range of $69 to $77 million and operating income before accounting for stock compensation in the range of $10 to $15 million. The company previously reported 2019 Outlook to be $58 to $68 million for revenues and operating income before accounting for stock compensation in the range of $4 to $10 million.